QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.
Wenjia ZuoZhonghua WangJun QianXiaopeng MaZhaofeng NiuJianghua OuQinguo MoJing SunXinzheng LiQitang WangYongzhong YaoGuohua YuHongsheng LiDedian ChenHao ZhangCuizhi GengGuangdong QiaoMengmeng ZhaoBaihui ZhangXiaoyan KangJin ZhangZhimin ShaoPublished in: British journal of cancer (2024)
Chinadrugtrials.org CTR20201073; ClinicalTrials.gov NCT04629846.
Keyphrases
- phase iii
- locally advanced
- double blind
- open label
- rectal cancer
- epidermal growth factor receptor
- placebo controlled
- clinical trial
- neoadjuvant chemotherapy
- metastatic breast cancer
- squamous cell carcinoma
- phase ii
- phase ii study
- radiation therapy
- study protocol
- tyrosine kinase
- cross sectional
- randomized controlled trial
- breast cancer cells
- smoking cessation